India Pharma Outlook Team | Thursday, 16 July 2026
Cadila Rejects Aciloc Ban Reports has become the latest talking point after the company issued a detailed clarification.
Cadila Pharmaceuticals said there is no order stopping the manufacture, sale, or distribution of Aciloc 150+ and Aciloc 300+ products.
The company also confirmed that supplies continue without any disruption. Cadila Rejects Aciloc Ban Reports as it maintained that both products meet all applicable national regulatory requirements. The medicines remain available across pharmacies, according to the company.
Cadila said Aciloc 150+ and Aciloc 300+ contain famotidine, a histamine H2 receptor antagonist used to treat acid-related disorders. The company clarified that the active pharmaceutical ingredient has always been clearly mentioned on the packaging and labels.
According to Cadila, the labeling follows all applicable regulatory requirements. The company said both medicines continue to comply with national rules and remain available in the market.
Cadila also said its scientific and regulatory teams are reviewing the matter carefully. The teams are working with the relevant authorities to examine every aspect.
Arani Chatterjee, President of Cadila Pharmaceuticals, said patient safety remains the company's highest priority. He said the active pharmaceutical ingredient is clearly mentioned on every Aciloc pack.
He added that the company is fully cooperating with the authorities during the review process. He also said Cadila remains focused on maintaining confidence in the quality, safety, and proper use of its medicines.
Also Read: Top 10 Performing Indian Pharma Stocks This Quarter (2026)
Cadila highlighted several key points in its statement:
Cadila said it will continue to ensure uninterrupted availability of its medicines across the market. The company also reiterated its commitment to quality, patient safety, and regulatory compliance.
The clarification comes as questions were raised over the company's Aciloc products. Cadila responded by stating that there is no regulatory order preventing the products from reaching consumers.
The company maintained that its medicines meet the required standards. It also said it will continue cooperating with the concerned authorities while the matter is reviewed.
Cadila emphasized that consumers and healthcare providers can continue accessing Aciloc 150+ and Aciloc 300+ through regular pharmacy channels. The company said it remains committed to transparency and compliance with all applicable regulations.
